Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer

An Open-Label Comparative Cohort Trial
  • Sergio Maluta
  • Moshe SchafferEmail author
  • Fabio Pioli
  • Stefano Dall’Oglio
  • Stefano Pasetto
  • Pamela M. Schaffer
  • Bernard Weber
  • Maria Grazia Giri
Original Article


To evaluate the therapeutic effect of delivering regional hyperthermia (HT) plus chemoradiotherapy (CRT) in patients suffering from locally advanced unresectable pancreatic cancer (LAPC).


Between January 2000 and December 2008, 68 patients affected by primary (56/68) or recurrent (12/68) LAPC were treated either with CRT alone or CRT plus HT. Radiotherapy (RT) consisted of 3D conformal irradiation of tumor and regional lymph nodes (dose ranged from 30 Gy/10 fractions to 66 Gy/33 fractions). Chemotherapy (CT) consisted of gemcitabine (GEM) alone or in association with either oxaliplatin, cisplatin, or 5-FU. HT was delivered twice a week, concomitant with RT.


In the current study, 60 of the original 68 patients were included. Median overall survival (OS) was 15 months in the HT group versus 11 months in the control group (log-rank test: p = 0.025). HT did not increase CRT toxicity.


HT can be added safely to CRT in LAPC, thus, resulting in slightly prolonged survival in certain cases.

Key Words

Pancreatic cancer Hyperthermia Chemoradiotherapy 

Regionale Hyperthermie kombiniert mit Chemoradiotherapie bei Erstdiagnose oder Rezidiv eines primären oder rezidivierten lokal fortgeschrittenen Pankreaskarzinoms: eine offene Kohortenvergleichsstudie


Die Evaluierung des therapeutischen Effekts der regionalen Hyperthermie (HT), kombiniert mit Chemoradiotherapie (CRT) bei Patienten mit einem lokal fortgeschrittenen, nicht resektablen Pankreaskarzinom (LAPC).


Zwischen Januar 2000 und Dezember 2008 wurden 68 Patienten mit Erstdiagnose (56/68) oder Rezidiv (12/68) eines LAPC mit CRT alleine oder mit CRT in Kombination mit HT behandelt. Die RT wurde in Form einer 3D-konformalen Strahlentherapie appliziert. Das Zielvolumen umfasste den Tumor sowie die regionalen Lymphknoten (Dosis-Range von 30 Gy/10 Fraktionen bis zu 66 Gy/33 Fraktionen). Die Chemotherapie (CT) erfolgte mit Gemcitabin (GEM) alleine oder in Kombination mit Oxaliplatin, Cisplatin oder 5-FU. HT wurde zweimal wöchentlich in Kombination mit der RT appliziert.


60 von 68 Patienten konnten evaluiert werden. Das mediane Überleben (OS) war 15 Monate in der HAT-Gruppe versus 11 Monate in der Kontrollgruppe (Log- rank-Test: p = 0,025). Der Zusatz einer HT führt zu keiner Erhöhung der Nebenwirkungen der CRT.


Die HT kann ohne Bedenken einer CRT bei LAPC hinzugefügt werden und ermöglicht in bestimmten Fällen das OS zu verlängern.


Pankreaskarzinom Hyperthermie Chemoradiotherapie 


  1. 1.
    Adachi S, Kokura S, Okayama T et al. Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperthermia 2009;25:210–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19:1592–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen SJ, Dobelbower R Jr, Lipsitz S et al.; Eastern Cooperative Oncology Group. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 2005;62:1345–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Colucci G, Labianca R, Di Costanzo F et al. Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente (GISCAD), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Crane CH, Janjan NA, Evans DB et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Gastrointest Cancer 2001;29:9–18.PubMedCrossRefGoogle Scholar
  6. 6.
    Eckert F, Fehm T, Bamberg M Small cell carcinoma of vulva: curative multimodal treatment in face of resistance to initial standard chemotherapy. Strahlenther Onkol 2010;186:521–4.PubMedCrossRefGoogle Scholar
  7. 7.
    El-Rayes BF, Zalupski MM, Shields AF et al. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 2003;21:2920–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Eppinga W, Lagerwaard F, Verbakel W et al. Volumetric modulated arc therapy for advanced pancreatic cancer. Strahlenther Onkol 2010;186:382–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Goldstein D, van Hazel G, Selva-Nayagam S et al. GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). J Clin Oncol (Meeting Abstracts) 2009;27:4616.Google Scholar
  10. 10.
    Haddock MG, Kim GP, Foster NR. Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer (NCCTG 0349). ASCO Gastrointestinal Cancers Symposium, 19–21 January 2007, Orlando, Florida A-176.Google Scholar
  11. 11.
    Haveman J, Rietbroek RC, Geerdink A et al. Effect of hyperthermia on the cytotoxicity of 2′,2′-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 1995;62:627–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Huguet F, André T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Ishii H, Okada S, Tokuuye K et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Ishikawa T, Kokura S, Oyamada H et al. Effects of a sequential combination of hyperthermia and Gemcitabine in the treatment of advanced unresectable pancreatic cancer. Thermal Med 2008;24:131–9.CrossRefGoogle Scholar
  15. 15.
    Istomin YP, Zhavrid EA, Sachivko NV et al. The effect of cytostatics and hyperthermia on RAJI human lymphoma cells. Exp Oncol. 2011;33:19–23.PubMedGoogle Scholar
  16. 16.
    Kido Y, Kuwano H, Maehara Y et al. Increased cytotoxicity of low - dose, long duration exposure to 5 - fluorouracil of V - 79 cells with hyperthermia. Cancer Chemother Pharmacol 1991;:251–4.Google Scholar
  17. 17.
    Klautke G, Brunner TB. Radiotherapy in pancreatic cancer. Strahlenther Onkol 2008; 184:557–64.PubMedCrossRefGoogle Scholar
  18. 18.
    Kornek GV, Schratter-Sehn A, Marczell A et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 2000;82:98–103.PubMedCrossRefGoogle Scholar
  19. 19.
    Loehrer PJ Sr, Powell ME, Cardenes HR et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol (Meeting Abstracts) 2008;26:4506.Google Scholar
  20. 20.
    Louvet C, André T, Lledo G et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20:1512–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Mantel F, Frey B, Haslinger S et al. Combination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells. Strahlenther Onkol 2010;186:587–99.PubMedCrossRefGoogle Scholar
  22. 22.
    Matsuoka H, Sugimachi K, Abe R et al. Enhancement of cytotoxicity by hyperthermia after a long-term culture with 5-fluorouracil in transformed cells. Anticancer Res 1992;12:1621–5.PubMedGoogle Scholar
  23. 23.
    Meta M, Sawata T, Kaibara N. Effects of hyperthermia on the metabolism of 5-fluorouracil in vitro. Int J Hyperthermia 1993;9:105–13.CrossRefGoogle Scholar
  24. 24.
    Milani V, Pazos M, Issels RD et al. Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer. Strahlenther Onkol 2008;184:163–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Moertel CG, Frytak S, Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48:1705–10.PubMedCrossRefGoogle Scholar
  26. 26.
    Rau B, Wust P, Hohenberger P et al. Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase II clinical trial. Ann Surg 1998;227:380–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Sultana A, Tudur Smith C, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 2008;99:6–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Sultana A, Tudur Smith C, Cunningham D et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007; 96:1183–90.PubMedCrossRefGoogle Scholar
  29. 29.
    The Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751–5.CrossRefGoogle Scholar
  30. 30.
    Tinkl D, Grabenbauer GG, Golcher H et al. Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 2009;185:557–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Tschoep KE, Boeck S, Berger F et al. Regional hyperthermia (RHT) combined with gemcitabine (GEM) + cisplatin (CIS) in patients with GEM-refractory advanced pancreatic cancer: Results of the ESHO phase II trial. J Clin Oncol (Meeting Abstracts) 2008;26:4635.Google Scholar
  32. 32.
    Viret F, Ychou M, Baey C et al. A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09/0201 trial. J Clin Oncol (Meeting Abstracts) 2009;27:4625.Google Scholar
  33. 33.
    Wilkowski R, Boeck S, Ostermaier S et al. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer-a multi-centre randomised phase II study. Br J Cancer 2009;101:1853–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Yamazaki H, Nishiyama K, Koizumi M et al. Concurrent Chemoradiotherapy for Advanced Pancreatic Cancer 1,000 mg/m2 Gemcitabine can be Administered Using Limited-Field Radiotherapy. Strahlenther Onkol 2007;183:301–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Yip D, Karapetis C, Strickland A et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006 Jul 19;3:CD002093.PubMedGoogle Scholar

Copyright information

© Urban & Vogel 2011

Authors and Affiliations

  • Sergio Maluta
    • 1
  • Moshe Schaffer
    • 2
    • 5
    Email author
  • Fabio Pioli
    • 1
  • Stefano Dall’Oglio
    • 1
  • Stefano Pasetto
    • 1
  • Pamela M. Schaffer
    • 3
  • Bernard Weber
    • 3
  • Maria Grazia Giri
    • 4
  1. 1.Department of RadiotherapyUniversity HospitalVeronaItaly
  2. 2.Department of OncologyZiv Medical Center and School of MedicineZefatIsrael
  3. 3.Bad Trissl Oncology HospitalOberaudorfGermany
  4. 4.Department of Health PhysicsUniversity HospitalVeronaItaly
  5. 5.Department of OncologyZiv Medical Center and School of MedicineZefatIsrael

Personalised recommendations